Medicines & supplements – Current GIS Alerts 2026
Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Flegafortan
The patient leaflet regarding recommended dosing was inconsistent with the approved Summary of Product Characteristics, which could lead to incorrect use and overdose manifested by increased volume of bronchial secretions. Potential effects: overdose, worsening cough and adverse drug reactions.
Sulfarinol
The tested retention samples showed out-of-specification results for the parameter “naphazoline nitrate contamination – other single impurity”, which may indicate the presence of an undesirable chemical compound in the product. Potential effects: possible adverse effects, irritation, lack of efficacy or other unpredictable reactions.
Espumisan 100 mg/ml
In several packs of the product, information leaflets for the medicinal product Zentel were detected instead of the correct Espumisan leaflet. Potential effects: incorrect use of the medicine, risk of improper dosing or lack of treatment efficacy.
Lecalpin
The defect was reported due to the detection of Lecalpin 10 mg blisters, batch 268018, inside outer cartons intended for Lecalpin 20 mg. Potential effects: possible intake of an incorrect dose and reduced treatment efficacy.
Kalium effervescens bezcukrowy
Lack of a unique identifier and an anti-tampering device on the packaging of prescription-only products, which could hinder verification of authenticity and detection of package tampering. Potential effects: risk of falsified medicine or interference with the packaging, possible lack of efficacy or adverse effects.
Spasmolina
The non-compliance consisted in not placing on the packaging of prescription medicinal products the safety features: a unique identifier and an anti-tampering device. Potential effects: falsification of the medicine, misidentification, risk of lack of appropriate treatment.
Riflux
Contamination of the active substance Ranitidine with N-nitrosodimethylamine (NDMA) was detected, constituting a quality defect and a potential risk to patients’ health. Potential effects: possible toxic and carcinogenic effects during long-term use.
Debridat
A potential quality defect was reported due to the risk of a foreign body being present in the product, which may pose a real and direct risk to patients’ health or life. Potential effects: complications, tissue damage, life-threatening events.
Debridat
Risk of a potential quality defect consisting in the presence of a foreign body in the product. Potential effects: mechanical injuries, gastrointestinal complications, risk to health or life.
Debridat
Risk of the presence of a foreign body in the medicinal product, possibly due to a potential quality defect. Potential effects: mechanical damage to the gastrointestinal tract, complications, need for medical intervention.
Debridat
Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension. Potential effects: mechanical damage, complications, irritation of the gastrointestinal tract.
Debridat
Risk of the presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may cause gastrointestinal damage or other mechanical complications during use. Potential effects: mechanical injuries, complications, risk to health or life.
Debridat
Risk of a quality defect in the medicinal product Debridat, 7.87 mg/g, granules for oral suspension, due to the risk of the presence of a foreign body in the product. Potential effects: gastrointestinal injuries, complications, possible threat to the patient’s health or life.
Debridat
Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may expose the patient to mechanical damage of the gastrointestinal tract or other complications during use. Potential effects: injuries, complications, health risk.
Apra-swift
A printing inconsistency in the dose on one side of the outer packaging was found (15 mg stated incorrectly, it should be 30 mg). Potential effects: improper dosing, lack of treatment efficacy or adverse effects.
Raniberl Max
Contamination of the active substance ranitidine with N-nitrosodimethylamine (NDMA) was detected, causing the batches to be deemed non-compliant with quality requirements and potentially hazardous to patients’ health or life. Potential effects: carcinogenic action, organ damage, general poisoning.
Lakcid forte
The test showed that the product sample does not comply with the specification regarding the CFU count of lactic acid bacteria (Lactobacillus rhamnosus), which may mean a lower content of live probiotic bacteria than declared. Potential effects: lack of treatment efficacy, possible worsening of symptoms, delay of therapy.
Lakcid forte
It was found that the product sample does not comply with the specification regarding the number of lactic acid bacteria CFU, which may lead to reduced therapeutic effectiveness of the probiotic preparation. Potential effects: reduced treatment effectiveness, lack of the expected probiotic effect.
NuTRIflex Omega plus
Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating a quality defect of a solution intended for intravenous infusion. Potential effects: lack of therapeutic efficacy, metabolic disturbances, complications during parenteral nutrition.
Flavamed
A possible increased level of impurity E was identified in batches manufactured using glass bottles from one of the suppliers, which constitutes a quality defect of the medicinal product. Potential effects: possible adverse reactions or reduced treatment safety.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.